In today’s Wall Street Journal there is a fantastic opinion piece written by Dr. Mark Thornton, Black Wednesday at the FDA. Dr. Thornton points out that not only did the FDA not approve Provenge last Wednesday, but also it failed to approve Junovan, a immunological drug designed to treat young children with a rare bone [...]
For years, the pharmaceutical companies have been developing more then just drugs! Our treating physicians and our researchers have also been very creative, performing feats beyond what we normally give them credit. Together, they have created a cadre of patients who are guilty of not measuring up to the task while also avoiding any responsibility [...]
The controversy that has been haunting the FDA approval of Provenge (sipuleucel-T) still continues with major fireworks on all sides. I have written a number of pieces about Provenge in this blog, so if you are not familiar with this potential new treatment you might want to go back and read them. Pay particular attention [...]
The April 27th edition of Forbes Magazine (Health Day News) describes a new imaging technique that is currently being studied at the University of Michigan. The original study was published in the April 15 issue of Cancer Research. This technology measures the diffusion of water through tumors. As tumor cells die, the diffusion of water [...]
PSA Rising has just posted transcripts of the patient advocates testimony which was delivered to the FDA's Advisory Committee at the recent Provenge hearing. I have written extensively about the hearing and the role of patient advocates at this hearing in an earlier post. For anyone interested, six of the patient advocates testimony, including my [...]